AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27790333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactocare® (Synbiotic)
Number of subjects: 72
Study 24588298 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 149
Study 24588298 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 149
Study 22234929 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3 mg)
Number of subjects: 29
Study 22234929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19556719 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin + 300 mg rebamipide
Number of subjects: 20
Study 19556719 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin + placebo
Number of subjects: 20
Study 17886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy
Number of subjects: 0
Study 17886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternant chemotherapy
Number of subjects: 0
Study 17886708 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematologic support
Number of subjects: 0
Study 17886708 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain prophylactic radiotherapy
Number of subjects: 0
Study 17886708 — intervention group
Group type: EXPERIMENTAL
Intervention: New targeted therapy agents or immunotherapeutic approaches
Number of subjects: 0
Study 15793155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline at 200 mg every 24 h
Number of subjects: 17
Study 12165125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bond‐1
Number of subjects: 30
Study 12165125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT
Number of subjects: 30
Study 12165125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 30
Study 9861129 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-filled LMA cuff
Number of subjects: 20
Study 9861129 — intervention group
Group type: COMPARATOR
Intervention: Air-filled LMA cuff
Number of subjects: 20
Study 8519714 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic patient-controlled epidural fentanyl
Number of subjects: 30
Study 8519714 — intervention group
Group type: COMPARATOR
Intervention: Lumbar patient-controlled epidural fentanyl
Number of subjects: 30
Study 2194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 400 mg
Number of subjects: 168
Study 2194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 800 mg
Number of subjects: 168
Study 2194047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 369623 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5HTP) with carbidopa
Number of subjects: 31
Study 369623 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 31
Study 30543274 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stability Training (CST)
Number of subjects: 20
Study 30543274 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 28122161 — intervention group
Group type: EXPERIMENTAL
Intervention: Education empowerment program
Number of subjects: 108
Study 28122161 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 108
Study 25265255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus once-daily formulation (Tac-OD)
Number of subjects: 247
Study 25265255 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus twice-daily formulation (Tac-TD)
Number of subjects: 247
Study 23448746 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-36 acupressure
Number of subjects: 60
Study 23448746 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure (Control)
Number of subjects: 60
Study 21366473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (targeting a glycated hemoglobin level below 6.0%)
Number of subjects: 0
Study 21366473 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (targeting a glycated hemoglobin level of 7 to 7.9%)
Number of subjects: 0
Study 18298579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (ddI-EC) administered in a fasted state (group 1)
Number of subjects: 21
Study 18298579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (ddI-EC) administered with food (group 2)
Number of subjects: 21
Study 16946615 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouthwash
Number of subjects: 0
Study 16946615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with tap water
Number of subjects: 0
Study 16946615 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectorating only
Number of subjects: 0
Study 16946615 — intervention group
Group type: COMPARATOR
Intervention: Control (F‐free periods)
Number of subjects: 0
Study 12921431 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and response set switches in blocked condition
Number of subjects: 0
Study 12921431 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and response set switches in random condition with brief cue-to-target interval
Number of subjects: 0
Study 10918483 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/liposome formulation (plasmid DNA expressing CFTR cDNA complexed with DC‐Chol/DOPE cationic liposomes)
Number of subjects: 12
Study 10918483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9005590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 U (40 mg) administered once-a-day in the evening for 60 days
Number of subjects: 2
Study 9005590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 1419290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M (mitozantrone 6.5 mg/m2 q 21 days, methotrexate 30 mg/m2 q 21 days, mitomycin C 6.5 mg/m2 q 42 days)
Number of subjects: 105
Study 1419290 — intervention group
Group type: COMPARATOR
Intervention: 2M (as 3M but without mitomycin C)
Number of subjects: 105
Study 6732324 — intervention group
Group type: EXPERIMENTAL
Intervention: Open peritoneal lavage
Number of subjects: 118
Study 6732324 — intervention group
Group type: COMPARATOR
Intervention: Closed peritoneal lavage
Number of subjects: 118
Study 6732324 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraumbilical approach
Number of subjects: 118
Study 6732324 — intervention group
Group type: COMPARATOR
Intervention: Infraumbilical approach
Number of subjects: 118
Study 31370792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention A (advanced) including nutritional counseling, physical activity, cognitive training, optimization of medication, management of vascular risk factors, social activity, and specific interventions targeting grief and depression
Number of subjects: 1152
Study 31370792 — intervention group
Group type: COMPARATOR
Intervention: General health advice and GP treatment as usual (Intervention B)
Number of subjects: 1152
Study 30205830 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with trained PHC staff and community-based 'Healthy Living groups' co-led by Ashas using cognitive-behavioral strategies.
Number of subjects: 0
Study 30205830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 27876035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored DVD intervention provided preoperatively and used throughout the postoperative period
Number of subjects: 156
Study 27876035 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 156
Study 25691263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation (within 48 hours)
Number of subjects: 175
Study 25691263 — intervention group
Group type: COMPARATOR
Intervention: Late intubation (after 48 hours)
Number of subjects: 175
Study 23654022 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA)
Number of subjects: 250
Study 23654022 — intervention group
Group type: COMPARATOR
Intervention: Confirmatory Factor Analysis (CFA)
Number of subjects: 250
Study 21482863 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin gel (0.1% in hydrogel), applied once daily for 8 weeks
Number of subjects: 64
Study 21482863 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel dressing, applied once daily for 8 weeks
Number of subjects: 64
Study 21482863 — intervention group
Group type: COMPARATOR
Intervention: Becaplermin gel and Hydrogel dressing
Number of subjects: 64
Study 19917839 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (6 mg/kg every 3 weeks for 1 year)
Number of subjects: 3010
Study 19917839 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3010
Study 17029996 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and T (GHT)
Number of subjects: 69
Study 17029996 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 69
Study 17029996 — intervention group
Group type: EXPERIMENTAL
Intervention: T
Number of subjects: 69
Study 17029996 — intervention group
Group type: EXPERIMENTAL
Intervention: GHT
Number of subjects: 69
Study 17029996 — intervention group
Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 69
Study 12644426 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. diltiazem 1 micro g kg(‐1) min(‐1)
Number of subjects: 30
Study 12644426 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 30
Study 10709897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid regime A (60 ml/kg on day 1, increasing to 150 ml/kg over the first week)
Number of subjects: 168
Study 10709897 — intervention group
Group type: COMPARATOR
Intervention: Fluid regime B (approximately 20% less fluid than regime A over the first week)
Number of subjects: 168
Study 9090342 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief trauma/grief-focused psychotherapy
Number of subjects: 0
Study 9090342 — intervention group
Group type: COMPARATOR
Intervention: Not treated with psychotherapy
Number of subjects: 0
Study 7529606 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF
Number of subjects: 0
Study 7529606 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0
Study 7529606 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐3, interleukin‐6, and interleukin‐11
Number of subjects: 0
Study 3395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 1-gram preoperative dose followed by 4 additional postoperative doses at 6-hour intervals
Number of subjects: 150
Study 3395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 2-gram doses
Number of subjects: 150
Study 3395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2-gram doses
Number of subjects: 150
Study 3395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (5-gram course)
Number of subjects: 150
Study 30016417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-suspension seat
Number of subjects: 40
Study 30016417 — intervention group
Group type: COMPARATOR
Intervention: Passive air-suspension seat (control)
Number of subjects: 40
Study 28672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (two doses for 12 weeks)
Number of subjects: 122
Study 26582144 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially produced Scoparia dulcis porridge (SDC) for 3 days/week for three months
Number of subjects: 35
Study 26582144 — intervention group
Group type: COMPARATOR
Intervention: Control group (any other food)
Number of subjects: 35
Study 26582144 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially produced Scoparia dulcis porridge (SDC)
Number of subjects: 35
Study 24909528 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic science instruction
Number of subjects: 51
Study 24909528 — intervention group
Group type: COMPARATOR
Intervention: Clinically focused instruction
Number of subjects: 51
Study 22680836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (4 × 10^8 colony-forming units/die)
Number of subjects: 74
Study 22680836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 20145986 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT) group
Number of subjects: 0
Study 20145986 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control group
Number of subjects: 0
Study 18922988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin target of 9.5 to 11.5 g/dl
Number of subjects: 596
Study 18922988 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin target of 13.5 to 14.5 g/dl
Number of subjects: 596
Study 18922988 — intervention group
Group type: EXPERIMENTAL
Intervention: High hemoglobin target (13.5 to 14.5 g/dl)
Number of subjects: 596
Study 15549266 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis‐related kyphosis (O‐K) group
Number of subjects: 25
Study 12415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 12415439 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 12415439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 10507244 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg benfotiamin (S-benzoylthiamine-o-monophosphate, BTMP)
Number of subjects: 20
Study 10507244 — intervention group
Group type: COMPARATOR
Intervention: 100 mg thiamine mononitrate (TN)
Number of subjects: 20
Study 9174677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 248
Study 9174677 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 248
Study 9174677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 248
Study 9174677 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 248
Study 8251730 — intervention group
Group type: EXPERIMENTAL
Intervention: Youjiangzhi capsule
Number of subjects: 61
Study 8251730 — intervention group
Group type: COMPARATOR
Intervention: Mai-an Powder
Number of subjects: 61
Study 3798932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg i.v. t.i.d.
Number of subjects: 100
Study 3798932 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg i.v. b.i.d.
Number of subjects: 100
Study 31687178 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 12
Study 31687178 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 12
Study 30132960 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids nanomicelles (80 mg, three times daily, orally) plus mesalamine (3 g/24 hours, orally)
Number of subjects: 56
Study 30132960 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mesalamine (3 g/24 hours, orally)
Number of subjects: 56
Study 30132960 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids nanomicelles plus mesalamine
Number of subjects: 56
Study 27230934 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC GOLD catheter
Number of subjects: 40
Study 24789802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 50
Study 23208191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 20567009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates (90% alendronate, 10% etidronate)
Number of subjects: 154768
Study 18519002 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg one hour before surgery, then 200 mg every 12 hours for five days)
Number of subjects: 80
Study 18519002 — intervention group
Group type: COMPARATOR
Intervention: Control group (only PCA morphine)
Number of subjects: 80
Study 16042732 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine irrigation
Number of subjects: 250
Study 16042732 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose irrigation
Number of subjects: 250
Study 12502022 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10A 400-600 mg/day
Number of subjects: 35
Study 12502022 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10A 100-300 mg/day
Number of subjects: 35
Study 12502022 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10A 700-900 mg/day
Number of subjects: 35
Study 12502022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10748933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting direction at +60 degrees
Number of subjects: 0
Study 10748933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting direction at +30 degrees
Number of subjects: 0
Study 10748933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting direction at -60 degrees
Number of subjects: 0
Study 10748933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting direction at 0 degrees
Number of subjects: 0
Study 10748933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting direction at -30 degrees
Number of subjects: 0
Study 8536780 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 20
Study 8536780 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8403135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1)
Number of subjects: 42
Study 8403135 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (D)
Number of subjects: 42
Study 8403135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study 4028514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol content beer (reduced from 336.3 ml to 64.5 ml ethanol/week)
Number of subjects: 46
Study 4028514 — intervention group
Group type: COMPARATOR
Intervention: Normal drinking habits (baseline consumption)
Number of subjects: 46
Study 4028514 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in alcohol intake
Number of subjects: 46
Study 31373882 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week text messaging intervention (n=20)
Number of subjects: 40
Study 31373882 — intervention group
Group type: COMPARATOR
Intervention: No text messaging (n=20)
Number of subjects: 40
Study 29529146 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g milk protein beverage containing 4.2 g leucine (LEU)
Number of subjects: 22
Study 29529146 — intervention group
Group type: COMPARATOR
Intervention: 15 g mixed protein (milk and soy) beverage containing 1.3 g leucine (CON)
Number of subjects: 22
Study 27549509 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily) plus standard chemotherapy (cisplatin/etoposide)
Number of subjects: 157
Study 27549509 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily) plus standard chemotherapy (cisplatin/etoposide)
Number of subjects: 157
Study 23818429 — intervention group
Group type: EXPERIMENTAL
Intervention: Myotubes from physically active donors
Number of subjects: 18
Study 23818429 — intervention group
Group type: EXPERIMENTAL
Intervention: DAGs and ceramides in myotubes
Number of subjects: 18
Study 21960186 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 603
Study 21960186 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 603
Study 20021991 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 173
Study 20021991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 173
Study 18626531 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles, mumps and rubella (MMR) vaccination at 12 months
Number of subjects: 57
Study 15978764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (50 mAs)
Number of subjects: 16
Study 15978764 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (100 mAs)
Number of subjects: 16
Study 12449179 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 71
Study 12449179 — intervention group
Group type: COMPARATOR
Intervention: Conservative lifestyle strategy
Number of subjects: 71
Study 10355479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (jogging at 60-70% of VO2peak, 3 days/week for 35 min/session for 6 weeks)
Number of subjects: 13
Study 10355479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 13
Study 10355479 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 13
Study 8566681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate, metronidazole and amoxicillin (TG) for two weeks
Number of subjects: 60
Study 8566681 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OG) for four weeks
Number of subjects: 60
Study 1798306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) after 30 minutes
Number of subjects: 18
Study 1798306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) after 3 hours
Number of subjects: 18
Study 1798306 — intervention group
Group type: COMPARATOR
Intervention: Control group (before HBO)
Number of subjects: 18
Study 6248221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (2.0 gm IV infusion over 30 minutes)
Number of subjects: 10
Study 6248221 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2.0 gm IV infusion over 30 minutes)
Number of subjects: 10
Study 30268803 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tACS stimulation
Number of subjects: 0
Study 30268803 — intervention group
Group type: COMPARATOR
Intervention: sham (placebo) stimulation
Number of subjects: 0
Study 27100317 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus helveticus Lafti L10, 2 × 10 colony‐forming units)
Number of subjects: 30
Study 27100317 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 26055391 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 343
Study 26055391 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 343
Study 23361651 — intervention group
Group type: EXPERIMENTAL
Intervention: Art video producing positive and therapeutic 'insight' (Group A)
Number of subjects: 101
Study 23361651 — intervention group
Group type: COMPARATOR
Intervention: Art video with 'insight' unfavorable to psychological recovery (Group B)
Number of subjects: 101
Study 21500992 — intervention group
Group type: COMPARATOR
Intervention: Cetrorelix 0.25 mg/day
Number of subjects: 76